U.S. nephrology training program directors (TPDs) are increasingly joining forces to meet many of today’s current challenges. These efforts are spearheaded by the American Society of Nephrology’s (ASN) TPD executive committee. The committee consists of members elected by the TPD community to serve three-year terms, and is led by the ASN Education Director for Nephrology Fellowships.
TPDs and the TPD executive committee have been involved in several important issues of late, including participation in the national residency matching program and establishment of the in-training examination and geriatric nephrology curriculum.
On April 15, 2019, the results of the CREDENCE (1) and SONAR (2) trials were published. Both trials showed a 35% reduction in the relative risk of composite renal events in people with type 2 diabetes and kidney disease (DKD). Canagliflozin is now the first drug approved by the US Food and Drug Administration in almost two decades for slowing the progression of chronic kidney disease (CKD) in people with type 2 diabetes. By contrast, the future of endothelin receptor antagonists (ERAs) for treating DKD is uncertain. Various forums within the nephrology community have discussed aspects
The nephrology subspecialty, both at the fellow and practitioner level, has a greater percentage of international medical graduates (IMGs) than any other internal medicine subspecialty with the exception of geriatrics. As such, the contributions of IMGs to our field are tremendously important and we must work to continue to make nephrology an attractive career choice for them.
There are a number of challenges relating specifically to potential IMG fellows. Since J-1 and H1-B visa holders are not eligible for funding through the NIH, their options are substantially limited if they are interested in research training. Owing to limitations imposed by